奥氮平治疗精神分裂症患者的血药浓度参考范围研究.

To study the reference range of olanzapine concentration in the treatment of schizophrenia. METHODS: According to inclusion and exclusion criteria, age, gender, daily dose, administration time, daily administration frequency, drug combination, scale score and adverse drug reactions of inpatients from Xi’ an Mental Health Center from Jun. 2016 to Mar. 2022 were collected. The correlation between olanzapine concentration and collection index was analyzed. The effective reference range of olanzapine concentration was determined, and the warning value was determined combined with the incidence of adverse drug reactions. RESULTS: There were statistically significant differences in olanzapine concentration among patients with different ages and daily doses (F= 1. 138, F= 1. 322; P<0. 05), the olanzapine concentration of male patients was significantly lower than that of female patients [(39. 29±24. 48)ng / mL vs. (49. 93±26. 92) ng / mL, Kolmogorov-Smirnov test = 0. 201 4, P<0. 01)]. Olanzapine concentration was positively correlated with daily dose ratio (r = 0. 225 4, t = 36. 36, P<0. 01), adverse drug reactions ( t = 2. 013, P<0. 05). According to the principle of maximum detection rate value, 30 ng / mL was the lower limit of the reference range (≥ threshold detection rate was 8. 561%), 90 ng / mL was the upper limit of the reference range ( < threshold detection rate was 2. 022%), 130 ng / mL was the alert value ( adverse drug reaction rate ≥70%). The detection rate of 15 ng / mL was better than 90 ng / mL ( threshold detection rate: 4. 187% vs. 2. 022%). CONCLUSIONS: There are individual differences in patients using olanzapine with different gender, age and daily dose, and the incidence of adverse drug reactions is high, so that olanzapine concentration should be routinely monitored clinically. It is recommended that 15 to 90 ng / mL be used as the reference range and 130 ng / mL as the alert value. [ABSTRACT FROM AUTHOR]